Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update. "Regeneron had a strong third quarter marked by 11% ...

Nuance Pharma, our development partner for ensifentrine in Greater China announced it has ... It was good to see the approval of Dupixent for the treatment of COPD. I think it highlights the ...

and also showed improvements in lung function and health-related quality of life compared to placeboDupix Dupixent approved in China as the first-ever biologic medicine for patients with COPD ...

Dupixent is now approved for COPD in more than 30 countries, including the US and China, where COPD is a huge unmet medical need due to widespread [indiscernible] in the local population.

SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.

Sanofi's existing product line boasts several top-tier drugs, including immunology drug Dupixent, an IL-4/IL-13 ... obstructive pulmonary disease (COPD) will help the drug serve additional patients.